Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00002-5340-60 00002-5340 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-5562-60 00002-5562 Selpercatinib RETEVMO 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6082-60 00002-6082 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6120-60 00002-6120 Selpercatinib RETEVMO 120.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00009-0082-02 00009-0082 Irinotecan hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 24, 2024 In Use
00069-0252-30 00069-0252 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0353-30 00069-0353 Talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0454-30 00069-0454 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0546-30 00069-0546 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0655-30 00069-0655 Talazoparib Talzenna 0.75 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00069-0757-30 00069-0757 Talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral April 17, 2024 In Use
00078-1196-20 00078-1196 Asciminib SCEMBLIX 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral April 18, 2024 In Use
00143-9167-01 00143-9167 Eribulin mesylate ERIBULIN MESYLATE 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous June 28, 2024 In Use
00245-0822-30 00245-0822 Everolimus TORPENZ 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0823-30 00245-0823 Everolimus TORPENZ 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0824-30 00245-0824 Everolimus TORPENZ 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00245-0825-30 00245-0825 Everolimus TORPENZ 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 24, 2024 In Use
00480-3290-01 00480-3290 Paclitaxel Paclitaxel 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous July 2, 2024 In Use
59651-0464-28 59651-0464 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0464-29 59651-0464 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0465-28 59651-0465 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
59651-0465-29 59651-0465 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral March 14, 2024 In Use
00781-3520-91 00781-3520 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2024 May 25, 2024 In Use
00781-3528-10 00781-3528 Cyclophosphamide Cyclophosphamide 500.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use
00781-3529-10 00781-3529 Cyclophosphamide Cyclophosphamide 1000.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 8, 2024 In Use

Found 10,000 results in 7 milliseconds — Export these results